12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Aldoxorubicin: SPA received

CytRx received an SPA from FDA for an open-label, international Phase III trial to compare aldoxorubicin vs. investigator's choice of chemotherapy in about 400 patients with metastatic, locally advanced or unresectable STS...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >